Maze Therapeutics (MAZE) Leases (2024 - 2026)

Maze Therapeutics has disclosed Leases across 3 years of filings, most recently posting $19.3 million for Q1 2026.

• Leases for Q1 2026 came in at $19.3 million, down 14.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $19.3 million (down 14.22% YoY), and the FY2025 annual result was $20.1 million, down 13.48% from the prior year.
• Leases came in at $19.3 million for Q1 2026 at Maze Therapeutics, down from $20.1 million in the prior quarter.
• In the past five years, Leases ranged from a high of $23.2 million in Q4 2024 to a low of $19.3 million in Q1 2026.
• The 3-year median for Leases is $21.3 million (2025), against an average of $21.3 million.
• Across the five-year window, Leases declined 13.48% in 2025 and declined 14.22% in 2026, its largest moves.
• Maze Therapeutics' Leases stood at $23.2 million in 2024, then retreated by 13.48% to $20.1 million in 2025, then declined by 4.13% to $19.3 million in 2026.
• The last three Leases figures came in at $19.3 million (Q1 2026), $20.1 million (Q4 2025), and $20.9 million (Q3 2025), per Business Quant data.